| pubmed-article:16317295 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16317295 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:16317295 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:16317295 | lifeskim:mentions | umls-concept:C1527249 | lld:lifeskim |
| pubmed-article:16317295 | lifeskim:mentions | umls-concept:C0123931 | lld:lifeskim |
| pubmed-article:16317295 | lifeskim:mentions | umls-concept:C0281534 | lld:lifeskim |
| pubmed-article:16317295 | lifeskim:mentions | umls-concept:C1511237 | lld:lifeskim |
| pubmed-article:16317295 | lifeskim:mentions | umls-concept:C1705509 | lld:lifeskim |
| pubmed-article:16317295 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:16317295 | lifeskim:mentions | umls-concept:C1550436 | lld:lifeskim |
| pubmed-article:16317295 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:16317295 | lifeskim:mentions | umls-concept:C0701185 | lld:lifeskim |
| pubmed-article:16317295 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:16317295 | pubmed:dateCreated | 2005-11-30 | lld:pubmed |
| pubmed-article:16317295 | pubmed:abstractText | Concerns about the safety of irinotecan (CPT-11) plus bolus 5-fluorouracil (5-FU)/leucovorin (LV) (the so-called Saltz regimen) have been previously reported. This prospective, multicenter, non-randomized study evaluated the anti-tumoral effect and toxicity of the Saltz regimen as first-line chemotherapy of 130 patients with advanced colorectal cancer (CRC). The median numbers of treatment cycles and infusions received per patient were 3 and 12, respectively. Eight (6.1) and 37 patients (28.5%) showed complete and partial responses, respectively [overall response rate=34.6% (95% confidence interval=20.7-48.5%)]. After a median follow up period of 9 months, 70 patients had died. The median progression-free survival and overall survival were 6.78 (0.3-33.8) and 8.26 months (range 0.3-33.8), respectively. The combined CPT-11/5-FU/LV treatment was well tolerated and no toxic deaths were reported. The most common grade 3/4 hematological toxicity was neutropenia (28% of patients and 3% of infusions), but no febrile neutropenia was reported. Delayed diarrhea was the most reported grade 3/4 non-hematological toxicity (21% of patients and 2% of infusions). Other non-hematological toxicities showed very low incidences. During the study five patients died due to factors not associated with disease progression. We conclude that the Saltz regimen administered on an outpatient basis was safe and well tolerated in patients with advanced CRC. Close monitoring of external patients together with an early treatment of toxicity was found to be essential to prevent severe and potentially fatal gastrointestinal or thromboembolic events previously reported with this CPT-11 combined regimen. | lld:pubmed |
| pubmed-article:16317295 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16317295 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16317295 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16317295 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16317295 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16317295 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16317295 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16317295 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16317295 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:16317295 | pubmed:issn | 0959-4973 | lld:pubmed |
| pubmed-article:16317295 | pubmed:author | pubmed-author:RamosManuelM | lld:pubmed |
| pubmed-article:16317295 | pubmed:author | pubmed-author:RiveraFernand... | lld:pubmed |
| pubmed-article:16317295 | pubmed:author | pubmed-author:BalcellsMique... | lld:pubmed |
| pubmed-article:16317295 | pubmed:author | pubmed-author:BarcelóRamónR | lld:pubmed |
| pubmed-article:16317295 | pubmed:author | pubmed-author:López... | lld:pubmed |
| pubmed-article:16317295 | pubmed:author | pubmed-author:NavalónMartaM | lld:pubmed |
| pubmed-article:16317295 | pubmed:author | pubmed-author:GarcíaGirónCa... | lld:pubmed |
| pubmed-article:16317295 | pubmed:author | pubmed-author:AlonsoMartina... | lld:pubmed |
| pubmed-article:16317295 | pubmed:author | pubmed-author:CastañónCarme... | lld:pubmed |
| pubmed-article:16317295 | pubmed:author | pubmed-author:CentellesMarg... | lld:pubmed |
| pubmed-article:16317295 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16317295 | pubmed:volume | 17 | lld:pubmed |
| pubmed-article:16317295 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16317295 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16317295 | pubmed:pagination | 89-94 | lld:pubmed |
| pubmed-article:16317295 | pubmed:meshHeading | pubmed-meshheading:16317295... | lld:pubmed |
| pubmed-article:16317295 | pubmed:meshHeading | pubmed-meshheading:16317295... | lld:pubmed |
| pubmed-article:16317295 | pubmed:meshHeading | pubmed-meshheading:16317295... | lld:pubmed |
| pubmed-article:16317295 | pubmed:meshHeading | pubmed-meshheading:16317295... | lld:pubmed |
| pubmed-article:16317295 | pubmed:meshHeading | pubmed-meshheading:16317295... | lld:pubmed |
| pubmed-article:16317295 | pubmed:meshHeading | pubmed-meshheading:16317295... | lld:pubmed |
| pubmed-article:16317295 | pubmed:meshHeading | pubmed-meshheading:16317295... | lld:pubmed |
| pubmed-article:16317295 | pubmed:meshHeading | pubmed-meshheading:16317295... | lld:pubmed |
| pubmed-article:16317295 | pubmed:meshHeading | pubmed-meshheading:16317295... | lld:pubmed |
| pubmed-article:16317295 | pubmed:meshHeading | pubmed-meshheading:16317295... | lld:pubmed |
| pubmed-article:16317295 | pubmed:meshHeading | pubmed-meshheading:16317295... | lld:pubmed |
| pubmed-article:16317295 | pubmed:meshHeading | pubmed-meshheading:16317295... | lld:pubmed |
| pubmed-article:16317295 | pubmed:meshHeading | pubmed-meshheading:16317295... | lld:pubmed |
| pubmed-article:16317295 | pubmed:meshHeading | pubmed-meshheading:16317295... | lld:pubmed |
| pubmed-article:16317295 | pubmed:meshHeading | pubmed-meshheading:16317295... | lld:pubmed |
| pubmed-article:16317295 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16317295 | pubmed:articleTitle | Irinotecan (CPT-11) combined with bolus 5-fluorouracil/leucovorin (Saltz regimen) as first-line chemotherapy of patients with advanced colorectal cancer. | lld:pubmed |
| pubmed-article:16317295 | pubmed:affiliation | Hospital de Cruces Osakidetza, Barakaldo-Vizcaya, Spain. jrbarcelo@hcru.osakidetza.net | lld:pubmed |
| pubmed-article:16317295 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16317295 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:16317295 | pubmed:publicationType | Multicenter Study | lld:pubmed |
